Last Updated: November 8, 2026

VIGAFYDE Drug Patent Profile

Name: VIGAFYDE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Vigafyde patents expire, and when can generic versions of Vigafyde launch?

Vigafyde is a drug marketed by Pyros Pharms and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in VIGAFYDE is vigabatrin. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the vigabatrin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vigafyde

A generic version of VIGAFYDE was approved as vigabatrin by PH HEALTH on April 27^th, 2017.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for VIGAFYDE?
What are the global sales for VIGAFYDE?
What is Average Wholesale Price for VIGAFYDE?

Summary for VIGAFYDE

US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	4,470
What excipients (inactive ingredients) are in VIGAFYDE?	VIGAFYDE excipients list
DailyMed Link:	VIGAFYDE at DailyMed

Drug patent expirations by year for VIGAFYDE

Pharmacology for VIGAFYDE

Drug Class	Anti-epileptic Agent

US Patents and Regulatory Information for VIGAFYDE

VIGAFYDE is protected by three US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pyros Pharms	VIGAFYDE	vigabatrin	SOLUTION;ORAL	217684-001	Jun 17, 2024		RX	Yes	Yes	12,576,054	⤷ Start Trial	Y			⤷ Start Trial
Pyros Pharms	VIGAFYDE	vigabatrin	SOLUTION;ORAL	217684-001	Jun 17, 2024		RX	Yes	Yes	12,016,857	⤷ Start Trial	Y			⤷ Start Trial
Pyros Pharms	VIGAFYDE	vigabatrin	SOLUTION;ORAL	217684-001	Jun 17, 2024		RX	Yes	Yes	12,290,499	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for VIGAFYDE

See the table below for patents covering VIGAFYDE around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
United Kingdom	202103724		⤷ Start Trial
United Kingdom	2591389	Pharmaceuticals solution for oral dosage	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2020039262		⤷ Start Trial
World Intellectual Property Organization (WIPO)	2024058812		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.